Support WBURGene Therapy Shows Promise For Hemophilia, But Could Be Most Expensive U.S. Drug EverPlay05:25Download AudioRob SteinJuly 20, 2020 ShareBiomarin Pharmaceutical, a California company that makes what could become the first gene therapy for hemophilia, says its drug's price tag might be $3 million per patient. (Getty Images)
